Stockscreener 앱 받기
7.68
0.39%
0.03
전일 마감가:
$7.65
열려 있는:
$7.7
하루 거래량:
467.45K
Relative Volume:
0.60
시가총액:
$547.76M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-2.6574
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
+6.22%
1개월 성능:
-9.00%
6개월 성능:
-52.91%
1년 성능:
-52.09%
1일 변동 폭
$7.58
$7.78
1주일 범위
$6.92
$8.24
52주 변동 폭
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
XNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
7.68 | 545.62M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Is it time to cut losses on Xencor Inc.Gold Moves & AI Forecast for Swing Trade Picks - Newser
Advanced analytics toolkit walkthrough for Xencor Inc.Market Performance Recap & Growth Focused Stock Pick Reports - Newser
Using fundamentals and technicals on Xencor Inc.Market Performance Recap & Breakout Confirmation Alerts - Newser
What earnings revisions data tells us about Xencor Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Using data tools to time your Xencor Inc. exitRisk Management & Technical Pattern Alert System - Newser
Heatmap analysis for Xencor Inc. and competitorsJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
Regression analysis insights on Xencor Inc. performanceJuly 2025 WrapUp & Fast Gain Swing Alerts - Newser
How Xencor Inc. stock performs during market volatilityWeekly Profit Recap & AI Driven Price Predictions - Newser
Xencor Inc. stock trend outlook and recovery pathQuarterly Profit Review & Short-Term High Return Ideas - Newser
What’s the analyst consensus on Xencor Inc.July 2025 Opening Moves & Capital Efficient Trading Techniques - thegnnews.com
Will Xencor Inc. Sustain Its Chart Breakout2025 Price Action Summary & Long-Term Capital Growth Strategies - metal.it
Xencor’s SWOT analysis: biotech stock faces pivotal clinical trials - Investing.com
Wedbush Estimates Xencor’s Q3 Earnings (NASDAQ:XNCR) - Defense World
William Blair Analysts Boost Earnings Estimates for Xencor - Defense World
Using portfolio simulators with Xencor Inc. includedEntry Confirmation Using Short-Term Forecasting - Newser
Wedbush Cuts Xencor (NASDAQ:XNCR) Price Target to $26.00 - Defense World
Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - uk.finance.yahoo.com
Xencor price target lowered to $26 from $31 at Wedbush - Yahoo Finance
Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology - TipRanks
Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment - TipRanks
Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment - TipRanks
Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating - TipRanks
Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating - MarketScreener
Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Xencor 2025 Q2 Earnings Strong Revenue Growth, 55.2% Reduction in Net Loss - AInvest
Xencor Inc earnings beat by $0.31, revenue topped estimates - Investing.com India
Xencor Reports Second Quarter 2025 Financial Results - BioSpace
Xencor, Inc. Reports Revenue Growth Amidst Continued Losses - TipRanks
Xencor: Q2 Earnings Snapshot - San Antonio Express-News
Xencor Q2 Earnings: Losses Reported but Revenue Surpasses ExpectationsNews and Statistics - IndexBox
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor (XNCR) Q2 Revenue Jumps 82% - sharewise.com
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking - simplywall.st
Published on: 2025-08-06 00:25:22 - Newser
What’s the recovery path for long term holders of Xencor Inc.Free Pattern Detection for Entry Confirmation - Newser
Xencor Inc. Flashes Rebound Signal in Oversold ConditionConfirmed Setup With Expert Accuracy Supported - metal.it
How does Xencor Inc. generate profit in a changing economyRapid market gains - Jammu Links News
What is the dividend policy of Xencor Inc. stockMaximize portfolio value with expert tips - Jammu Links News
When is Xencor Inc. stock expected to show significant growthSuperior capital gains - Jammu Links News
What is Xencor Inc. company’s growth strategyLightning-fast growth - Jammu Links News
Is it the right time to buy Xencor Inc. stockSky-high return potential - Jammu Links News
How many analysts rate Xencor Inc. as a “Buy”Overwhelming profit margins - Jammu Links News
What catalysts could drive Xencor Inc. stock higher in 2025Strong return on investment - Jammu Links News
How does Xencor Inc. compare to its industry peersConsistent triple returns - Jammu Links News
Should I hold or sell Xencor Inc. stock in 2025Triple-digit growth rates - Jammu Links News
Is Xencor Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is Xencor Inc. a good long term investmentCapitalize on market momentum for big wins - Jammu Links News
Xencor Appoints Raymond Deshaies to Board of Directors to Bolster Drug Development Efforts - AInvest
How volatile is Xencor Inc. stock compared to the marketJaw-dropping returns - Jammu Links News
Xencor (XNCR) Expected to Announce Quarterly Earnings on Monday - Defense World
Xencor XNCR 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth - AInvest
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xencor Inc 주식 (XNCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
0.41%
0.88%
자본화:
|
볼륨(24시간):